Results 171 to 180 of about 13,807 (248)
Exploring the Role of Nuclear Factor Kappa B in the Immunobiology of Inflammatory Neuropathies. [PDF]
Nagappa M +7 more
europepmc +1 more source
Cancer pain: current practice and emerging targets
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye +5 more
wiley +1 more source
Radiomics Applied to the Diagnosis of Peripheral Nerve Disorders: A Systematic Review and Meta-Analysis of the Existing Literature. [PDF]
Armato V +9 more
europepmc +1 more source
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, but their efficacy continues to be limited by immune‐related adverse events. Among these, ICI‐induced cardiac arrhythmias are increasingly recognised as a major adverse reaction, encompassing a broad spectrum of clinical phenotypes, including conduction blocks, atrial fibrillation and
Anand R. Ramalingam +3 more
wiley +1 more source
Development and Validation of a Visual Grading Score of Disease Severity From Gait Videos in Genetic Peripheral Neuropathy. [PDF]
Pernice HF +4 more
europepmc +1 more source
Peripheral targets for neuropathic pain
Neuropathic pain represents a significant clinical challenge, with still limited pharmacological approaches to symptomatic relief. This review focuses on molecular targets implicated in neuropathic pain, particularly those involved in peripheral mechanisms. Using the IUPHAR/BPS database of biological targets, their occurrence together with ‘neuropathic
Amirhossein Afsharipour +3 more
wiley +1 more source
Diabetic impact on the neuroaxis: from peripheral neuropathy to central neurodegeneration. [PDF]
Okdahl T, Brock C.
europepmc +1 more source
The flow of this trial and the treatment schedule of adjuvant chemotherapy with nedaplatin plus docetaxel for completely resected non‐small cell lung cancer (NSCLC) (A). The primary endpoint of this study was tolerability, assessed by the completion rate of the planned four chemotherapy cycles. As a result, it was 74.3%, exceeding that reported for the
Koji Teramoto +9 more
wiley +1 more source
B Vitamin Deficiencies and Associated Neuropathies. [PDF]
Alvarez M +6 more
europepmc +1 more source
ABSTRACT Objective To explore the associations between major modifiable risk factors and hearing loss. Methods This serial cross‐sectional study was conducted within the National Health and Nutrition Examination Survey 1999–2020 in the United States. Associations were assessed using modified Poisson regression and within‐sample population attributable ...
Yulu Zheng +5 more
wiley +1 more source

